Methods and Compositions for the Diagnosis of Neuroendocrine Lung Cancer
Background:
The National Cancer Institute's
Laboratory of Human Carcinogenesis is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize methods for
the diagnosis of neuroendocrine lung cancer.
Technology:
This technology relates to the
use of cDNA microarrays to facilitate the identification of
pulmonary neuroendocrine tumors. In order to identify molecular
markers that could be used to classify pulmonary tumors, the
inventors examined the gene expression profiles of clinical samples
from patients with small cell lung cancer (SCLC), large cell
neuroendocrine carcinoma (LCNEC), and typical carcinoma (TC) tumors
by cDNA microarray analysis. They detected hybridization between
cDNA from tumor cells and DNA from a panel of 8,897 human genes.
Gene expression was found to be nonrandom and to exhibit highly
significant clustering that divided the tumors into their assigned
World Health Organization (WHO) classification with 100% accuracy.
The inventors concluded that pulmonary neuroendocrine tumors could
be classified based on the genome-wide expression profile of the
clinical samples without further manipulations. This technology
provides an accurate, rapid, and easy method to diagnose pulmonary
neuroendocrine cancer and to differentiate three types of pulmonary
neuroendocrine tumors.
R&D Status:
The technology is currently in the pre-clinical stage of
development.
IP Status:
U.S. Patent Application No. 10/533,459 filed 02 May 2005
Value Proposition:
- Ability to diagnose pulmonary neuroendocrine cancer accurately,
rapidly, and efficiently
- Ability to differentiate three types of pulmonary
neuroendocrine tumors
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #648 KB
Posted 04/28/2008